GlucoTrack, Inc. GCTK

Glucotrack, Inc.'s subsidiary Lōkahi Therapeutics collaborates with Pepperdine E2B to involve MBA students in its ai2 Pipeline program for the coming academic year. Full-time MBA teams will work with Lōkahi professionals to identify, evaluate, and prioritize therapeutic opportunities, analyzing scientific, regulatory, IP, commercial, and strategic factors across asset lifecycles. The goal is to broaden asset sourcing and sustain a disciplined, capital-efficient pipeline development process. In the ai2 Futures Lab’s first year, 64 students identified more than 45 potential assets, with several moving into active discussions. Executives say the collaboration blends disciplined human judgment with data analytics to surface overlooked opportunities and strengthen long-term value creation. Pepperdine’s E2B partnership expands Lōkahi’s university network and pipeline-access capabilities. Expands pipeline sourcing and capital-efficient development, potentially altering long-term trajectory but contingent on execution.

Glucotrack, Inc. priced a best-efforts public offering to raise about $3.1 million, selling 169,388 common shares at $2.04 and pre-funded warrants to buy up to 1,350,220 shares at $2.039 per warrant. Proceeds are before placement-agent fees and offering expenses, with closing expected around Sept. 25, 2026. Dawson James Securities, Inc. is the sole placement agent. The offering is being made under a Form S-3 registration statement effective Oct. 3, 2024. The release includes forward-looking statements and risk factors. Glucotrack also references Lokahi Therapeutics, its platform-focused subsidiary, and notes that its Glucotrack CBGM device is investigational. Significant potential dilution from 1.35 million pre-funded warrants could materially affect future equity value.

Glucotrack, Inc. subsidiary Lōkahi Therapeutics announced Innovate GBM, a glioblastoma-focused nonprofit, has engaged two ai² PIPELINE project teams to identify and evaluate brain-tumor assets for licensing and development on a fee-for-service basis. This makes Innovate GBM the first external sponsor to access Lōkahi's asset-identification process, expanding the ai² platform from internal discovery to an externally usable model and leveraging a network of 14 university collaborations. Innovate GBM will independently decide whether to pursue any identified assets. The move broadens ai²'s reach to pharma, biotech, and investment groups, signaling a scalable, sponsor-driven pathway for differentiated opportunities. External sponsor engagement demonstrates monetization potential and scalability of the ai² PIPELINE, signaling a meaningful revenue and growth pathway for Glucotrack's platform business.

Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson outlined progress after their July merger, prioritizing LT-100 for osteoarthritis knee pain and expanding the ai² platform (Pipeline, Talent, Accelerator) to identify, advance, and monetize overlooked late-stage assets. LT-100 protocol was submitted for regulatory review and may begin soon, with a once-weekly subcutaneous regimen vs. prior 15 intradermal injections. The plan includes converting ai² candidates into in-house programs, launching Qare, growing the university network, and pursuing licensing or royalty deals. Glucotrack remains focused on continuous glucose monitoring technology as a subsidiary; the merger funds Glucotrack while Lōkahi drives asset development and monetization. The company aims to build a capital-efficient clinical-stage platform by leveraging external programs and disciplined execution, subject to Nasdaq and regulatory approvals. LT-100 progress and ai² platform expansion create near-term value opportunities and monetization potential, influencing future trajectory and investor sentiment.

GlucoTrack, Inc. announces $11.5 million financing. $11.5 million financing supplies capital to advance operations and product efforts.

Lōkahi Therapeutics expands ai² into three opportunity-creating business divisions. Expansion into three divisions signals moderate strategic growth potential for operations and market positioning.

GlucoTrack, Inc. (GCTK) announces a reverse stock split. Reverse stock split signals potential listing compliance issues and can pressure share price and sentiment.

Lōkahi Therapeutics initiates clinical trial manufacturing for LT-100. Clinical trial manufacturing start advances product development and may support future regulatory progress.

GlucoTrack, Inc. has regained compliance with Nasdaq equity requirements while advancing its strategic transformation. Regaining Nasdaq compliance removes delisting risk and bolsters market access during ongoing strategic shifts.

GlucoTrack achieves a key compliance milestone and advances its strategic transformation. Key compliance achievement and strategic transformation directly support regulatory progress and long-term repositioning for a medical device firm.

E.F. Hutton & Co. served as exclusive financial advisor for GlucoTrack, Inc.'s $5.5 million financing. $5.5 million financing supplies capital that supports GlucoTrack operations and development.

GlucoTrack, Inc. secures $5.5 million in financing. $5.5 million financing supplies capital to support operations and development.

Lōkahi Therapeutics advances LT-100 development strategy toward single-injection administration. LT-100 single-injection progress marks major development step that can shift product positioning and company prospects.

GlucoTrack combines with Lōkahi Therapeutics in a strategic business deal advised exclusively by E.F. Hutton, which also places $5.7 million in convertible notes. Strategic business combination and financing materially shift GlucoTrack's trajectory and market position.

GlucoTrack, Inc. and Lōkahi Therapeutics secure strategic financing support from E.F. Hutton & Co. after completing their business combination to back future capital markets initiatives. Financing support post-business combination provides capital access that may moderately improve financial positioning and market initiatives.

GlucoTrack and Lōkahi Therapeutics completed a strategic business combination that establishes Lōkahi control over the resulting public company platform. The completed combination transfers corporate control to Lōkahi and redefines GlucoTrack's ownership structure and strategic path.

GlucoTrack completes Lōkahi Therapeutics business combination, creating AI-driven healthcare platform. Business combination forms new AI healthcare platform expected to significantly alter company trajectory.

GlucoTrack, Inc. and Lōkahi Therapeutics completed a strategic business combination establishing Lōkahi-controlled public platform. Business combination transfers control to Lōkahi Therapeutics and fundamentally alters company structure and trajectory.

GlucoTrack clears key milestone toward commercializing its implantable CGM. Milestone advances implantable CGM commercialization and directly lifts future revenue prospects.

GlucoTrack announces USPTO notice of allowance for patent application covering its implantable CBGM platform. USPTO notice of allowance secures key patent protection for GlucoTrack core implantable glucose monitoring technology.

GlucoTrack will highlight its implantable continuous blood glucose monitoring technology at the American Diabetes Association’s 2026 Scientific Sessions. Conference presentation may increase visibility and partnerships for core glucose monitoring product.

GlucoTrack, Inc. (GCTK) reported first quarter 2026 financial results and recent corporate highlights. Quarterly financial results and corporate highlights represent major disclosures that can significantly sway investor sentiment and company trajectory.

GlucoTrack, Inc. (GCTK) submitted its implantable continuous blood glucose monitoring technology to the FDA for premarket approval. FDA submission marks a major regulatory milestone advancing commercialization of GCTK's core blood glucose monitoring device.

GlucoTrack, Inc. (GCTK) announced submission of an Investigational Device Exemption (IDE) to the FDA for a U.S. clinical study of its novel implantable continuous blood glucose monitoring technology. IDE submission represents a major regulatory milestone advancing GlucoTrack's implantable CGM toward U.S. clinical trials and potential commercialization.

GlucoTrack, Inc. (GCTK) demonstrates long-term accuracy of its implantable glucose monitor, highlighting reliable performance over extended periods. Long-term accuracy data validates the implantable glucose monitor's viability, potentially accelerating FDA approval and boosting investor confidence.

GlucoTrack announced publication of a peer-reviewed study in the Journal of Diabetes Research, demonstrating long-term accuracy and stability of its continuous blood glucose monitoring technology. Peer-reviewed study validating long-term CGM accuracy bolsters GlucoTrack's credibility, regulatory prospects, and market positioning.

A study supports GlucoTrack’s implantable blood glucose monitoring device, validating its accuracy and potential for continuous monitoring in diabetes patients. Study validation of core implant technology signals major progress toward commercialization, likely enhancing investor sentiment and competitive positioning.

GlucoTrack announced publication of a peer-reviewed study supporting the long-life sensor design for its implantable continuous blood glucose monitoring technology. Peer-reviewed study validates long-life sensor design, advancing GlucoTrack's implantable CGM technology and boosting investor confidence.

GlucoTrack, Inc. (GCTK) reported fourth quarter and full-year 2025 financial results along with recent corporate highlights. Q4 and full-year financial results plus corporate highlights moderately affect financial performance and investor sentiment.

GlucoTrack, Inc. (GCTK) plans to file for FDA exemption, leveraging key milestones targeted for 2025 to advance its non-invasive continuous glucose monitoring device toward market without full approval. FDA exemption filing pursuit signals major regulatory progress that could accelerate commercialization and transform competitive positioning.